Ad

Home / Reuters: Health News / At two years, Gilead lymphoma therapy active in 40 percent of patients

At two years, Gilead lymphoma therapy active in 40 percent of patients

Nearly 40 percent of lymphoma patients treated with a single infusion of Gilead Sciences Inc's Yescarta continued to respond to the cell therapy after at least two years of follow up, the company said on Sunday.


At two years, Gilead lymphoma therapy active in 40 percent of patients At two years, Gilead lymphoma therapy active in 40 percent of patients Reviewed by jenisht on December 02, 2018 Rating: 5

You May Also Like

No comments:

Subscribe to: Post Comments ( Atom )
Powered by Blogger.